{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22","upperLimit":"50","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"The percentage of patients experiencing treatment-related grade 3-4 adverse events based on CTCAEv3 as reported on case report forms.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive oral perifosine (150 mg) daily each cycle. Cycle duration is 28 days. After cycle 2, response is assessed and patients with stable or responding disease can continue for another 4 cycles or until disease progression (PD). Protocol treatment duration is 6 cycles but patients may receive perifosine maintenance per investigator discretion in absence of PD.","id":"OG000","title":"Perifosine"}],"paramType":"NUMBER","populationDescription":"The analysis dataset is comprised of all enrolled patients.","reportingStatus":"POSTED","timeFrame":"Adverse events were collected every cycle on treatment.The median treatment duration was 5.6 months (range, 1.8-21.5+).","title":"Treatment-Related Grade 3-4 Adverse Event Rate","type":"SECONDARY","unitOfMeasure":"percentage of patients"}